Association of oncolytic adenoviruses with chemotherapies: An overview and future directions

Biochemical Pharmacology

Volumn 90, Issue 2, 2014, Pages 97-106

  Bressy, Christian ^a,b   Benihoud, Karim ^a,b  

^a France   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Chemotherapeutic; CRAd; Oncolytic adenoviruses

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ALKYLATING AGENT; ANTHRACYCLINE; ANTIBIOTIC AGENT; BARASERTIB; BEVACIZUMAB; CETUXIMAB; CISPLATIN; DEPSIPEPTIDE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; IRINOTECAN; LONTUCIREV; MITOMYCIN; MITOXANTRONE; NAVELBINE; NOVATRONE; OBP 301; ONCOLYTIC ADENOVIRUS; PACLITAXEL; PHOSPHOTRANSFERASE INHIBITOR; ROMIDEPSIN; TAXANE DERIVATIVE; TELOMELYSIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINCA ALKALOID; VINCRISTINE; VINCRISTINE SULFATE;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL TRIAL; GENOME; HEAD AND NECK CANCER; HUMAN; IMMUNE RESPONSE; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL;

CHEMOTHERAPEUTIC; CRAD; ONCOLYTIC ADENOVIRUSES;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; GENOME, VIRAL; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VIRAL PROTEINS;

EID: 84902247576     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.05.003     Document Type: Note

References (73)

1. S.J. Russell, K.W. Peng, and J.C. Bell Oncolytic virotherapy Nat Biotechnol 30 2012 658 670
2. Fields BN, Knipe DM, Howley PM. Fields Virology. In: Knipe DM, Howley PM, Griffin DE, editors. Wolters Kluwer/Lippincott Williams & Wilkins: Philadelphia, PA, London; 2007.
3. M.B. Flinterman, J.S. Mymryk, P. Klanrit, A.F. Yousef, S.W. Lowe, and C. Caldas et al. p400 function is required for the adenovirus E1A-mediated suppression of EGFR and tumour cell killing Oncogene 26 2007 6863 6874 (Pubitemid 47609077)
4. W.S. Wold, and K. Toth Adenovirus vectors for gene therapy, vaccination and cancer gene therapy Curr Gene Ther 13 2013 421 433
5. M. Yamamoto, and D.T. Curiel Current issues and future directions of oncolytic adenoviruses Mol Ther 18 2010 243 250
6. C.C. O'Shea, L. Johnson, B. Bagus, S. Choi, C. Nicholas, and A. Shen et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity Cancer Cell 6 2004 611 623 (Pubitemid 40017704)
7. C. Heise, T. Hermiston, L. Johnson, G. Brooks, A. Sampson-Johannes, and A. Williams et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy Nat Med 6 2000 1134 1139
8. J. Fueyo, C. Gomez-Manzano, R. Alemany, P.S. Lee, T.J. McDonnell, and P. Mitlianga et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo Oncogene 19 2000 2 12 (Pubitemid 30066345)
9. G. Hallden, R. Hill, Y. Wang, A. Anand, T.C. Liu, and N.R. Lemoine et al. Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy Mol Ther 8 2003 412 424 (Pubitemid 37161463)
10. M.A. Thomas, J.F. Spencer, and W.S. Wold Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors Methods Mol Med 130 2007 169 183
11. I. Ganly, D. Kirn, G. Eckhardt, G.I. Rodriguez, D.S. Soutar, and R. Otto et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer Clin Cancer Res 6 2000 798 806 (Pubitemid 30159332)
12. J. Nemunaitis, F. Khuri, I. Ganly, J. Arseneau, M. Posner, and E. Vokes et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer J Clin Oncol 19 2001 289 298 (Pubitemid 32112839)
13. O. Hamid, M.L. Varterasian, S. Wadler, J.R. Hecht, A. Benson 3rd, and E. Galanis et al. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer J Clin Oncol 21 2003 1498 1504 (Pubitemid 46594102)
14. E.J. Small, M.A. Carducci, J.M. Burke, R. Rodriguez, L. Fong, and L. van Ummersen et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer Mol Ther 14 2006 107 117 (Pubitemid 43899483)
15. J. Nemunaitis, A.W. Tong, M. Nemunaitis, N. Senzer, A.P. Phadke, and C. Bedell et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors Mol Ther 18 2010 429 434
16. M.S. Ferguson, N.R. Lemoine, and Y. Wang Systemic delivery of oncolytic viruses: hopes and hurdles Adv Virol 2012 2012 805629
17. B.A. Chabner, and T.G. Roberts Jr. Timeline chemotherapy and the war on cancer Nat Rev Cancer 5 2005 65 72
18. V.T. DeVita Jr., and E. Chu A history of cancer chemotherapy Cancer Res 68 2008 8643 8653
19. M.A. Jordan, and L. Wilson Microtubules as a target for anticancer drugs Nat Rev Cancer 4 2004 253 265 (Pubitemid 38525281)
20. L. You, C.T. Yang, and D.M. Jablons ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients Cancer Res 60 2000 1009 1013 (Pubitemid 30129538)
21. D.C. Yu, Y. Chen, J. Dilley, Y. Li, M. Embry, and H. Zhang et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel Cancer Res 61 2001 517 525 (Pubitemid 32128610)
22. T. Fujiwara, S. Kagawa, H. Kishimoto, Y. Endo, M. Hioki, and Y. Ikeda et al. Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy Int J Cancer 119 2006 432 440
23. C.K. Ingemarsdotter, S.K. Baird, C.M. Connell, D. Oberg, G. Hallden, and I.A. McNeish Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer Oncogene 29 2010 6051 6063
24. E. Miranda, H. Maya Pineda, D. Oberg, G. Cherubini, Z. Garate, and N.R. Lemoine et al. Adenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-region PLoS ONE 7 2012 e46617
25. X. Song, H. Wang, R. Jia, B. Cun, X. Zhao, and Y. Zhou et al. Combined treatment with an oncolytic adenovirus and antitumor activity of vincristine against retinoblastoma cells Int J Mol Sci 13 2012 10736 10749
26. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol Rev 56 2004 185 229 (Pubitemid 38720829)
27. Y. Li, D.C. Yu, Y. Chen, P. Amin, H. Zhang, and N. Nguyen et al. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin Cancer Res 61 2001 6428 6436 (Pubitemid 32783248)
28. G. Portella, S. Scala, D. Vitagliano, G. Vecchio, and A. Fusco ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines J Clin Endocrinol Metab 87 2002 2525 2531 (Pubitemid 34655309)
29. H.C. Graat, M.A. Witlox, F.H. Schagen, G.J. Kaspers, M.N. Helder, and J. Bras et al. Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin Br J Cancer 94 2006 1837 1844 (Pubitemid 43882574)
30. G. Ma, K. Kawamura, Q. Li, S. Okamoto, N. Suzuki, and H. Kobayashi et al. Combinatory cytotoxic effects produced by E1B-55kDa-deleted adenoviruses and chemotherapeutic agents are dependent on the agents in esophageal carcinoma Cancer Gene Ther 17 2010 803 813
31. C. Heise, A. Sampson-Johannes, A. Williams, F. McCormick, D.D. Von Hoff, and D.H. Kirn ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents Nat Med 3 1997 639 645 (Pubitemid 27264973)
32. T. Reid, E. Galanis, J. Abbruzzese, D. Sze, L.M. Wein, and J. Andrews et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints Cancer Res 62 2002 6070 6079 (Pubitemid 35244455)
33. D. Liu, T. Kojima, M. Ouchi, S. Kuroda, Y. Watanabe, and Y. Hashimoto et al. Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer Mol Cancer Ther 8 2009 980 987
34. M. Raki, A. Kanerva, A. Ristimaki, R.A. Desmond, D.T. Chen, and T. Ranki et al. Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer Gene Ther 12 2005 1198 1205 (Pubitemid 41136314)
35. M. Takakura, M. Nakamura, S. Kyo, M. Hashimoto, N. Mori, and T. Ikoma et al. Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination Cancer Gene Ther 17 2010 11 19
36. A.R. Yoon, J.H. Kim, Y.S. Lee, H. Kim, J.Y. Yoo, and J.H. Sohn et al. Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin Hum Gene Ther 17 2006 379 390
37. Q. Gao, J. Zhou, X. Huang, G. Chen, F. Ye, and Y. Lu et al. Selective targeting of checkpoint kinase 1 in tumor cells with a novel potent oncolytic adenovirus Mol Ther 13 2006 928 937
38. Z. Han, Z. Hong, Q. Gao, C. Chen, Z. Hao, and T. Ji et al. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer Hum Gene Ther 23 2012 32 45
39. D. Fu, J.A. Calvo, and L.D. Samson Balancing repair and tolerance of DNA damage caused by alkylating agents Nat Rev Cancer 12 2012 104 120
40. I.V. Ulasov, A.M. Sonabend, S. Nandi, A. Khramtsov, Y. Han, and M.S. Lesniak Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo Br J Cancer 100 2009 1154 1164
41. M.M. Alonso, C. Gomez-Manzano, B.N. Bekele, W.K. Yung, and J. Fueyo Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter Cancer Res 67 2007 11499 11504
42. T. Yokoyama, E. Iwado, Y. Kondo, H. Aoki, Y. Hayashi, and M.M. Georgescu et al. Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells Gene Ther 15 2008 1233 1239
43. V. Cerullo, I. Diaconu, L. Kangasniemi, M. Rajecki, S. Escutenaire, and A. Koski et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus Mol Ther 19 2011 1737 1746
44. Y. Pommier Topoisomerase I inhibitors: camptothecins and beyond Nat Rev Cancer 6 2006 789 802 (Pubitemid 44450467)
45. B. Clifford, M. Beljin, G.R. Stark, and W.R. Taylor G2 arrest in response to topoisomerase II inhibitors: the role of p53 Cancer Res 63 2003 4074 4081 (Pubitemid 36917930)
46. C. Gomez-Manzano, M.M. Alonso, W.K. Yung, F. McCormick, D.T. Curiel, and F.F. Lang et al. Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan Clin Cancer Res 12 2006 556 562 (Pubitemid 43166149)
47. G. Cherubini, C. Kallin, A. Mozetic, K. Hammaren-Busch, H. Muller, and N.R. Lemoine et al. The oncolytic adenovirus AdDeltaDelta enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models Gene Ther 18 2011 1157 1165
48. A. Bieler, K. Mantwill, T. Dravits, A. Bernshausen, G. Glockzin, and N. Kohler-Vargas et al. Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520 Hum Gene Ther 17 2006 55 70 (Pubitemid 43100515)
49. S. Radhakrishnan, E. Miranda, M. Ekblad, A. Holford, M.T. Pizarro, and N.R. Lemoine et al. Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts Hum Gene Ther 21 2010 1311 1325
50. A. Palazzo, R. Iacovelli, and E. Cortesi Past, present and future of targeted therapy in solid tumors Curr Cancer Drug Targets 10 2010 433 461
51. D. Benjamin, M. Colombi, C. Moroni, and M.N. Hall Rapamycin passes the torch: a new generation of mTOR inhibitors Nat Rev Drug Discov 10 2011 868 880
52. K. Homicsko, A. Lukashev, and R.D. Iggo RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer Cancer Res 65 2005 6882 6890 (Pubitemid 41060727)
53. M.M. Alonso, H. Jiang, T. Yokoyama, J. Xu, N.B. Bekele, and F.F. Lang et al. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death Mol Ther 16 2008 487 493 (Pubitemid 351314987)
54. P.H. Cheng, S. Lian, R. Zhao, X.M. Rao, K.M. McMasters, and H.S. Zhou Combination of autophagy inducer rapamycin and oncolytic adenovirus improves antitumor effect in cancer cells Virol J 2013 10
55. G. Botta, C. Passaro, S. Libertini, A. Abagnale, S. Barbato, and A.S. Maione et al. Inhibition of autophagy enhances the effects of E1A-defective oncolytic adenovirus dl922-947 against glioma cells in vitro and in vivo Hum Gene Ther 23 2012 623 634
56. S. Arena, and A. Bardelli Understanding how kinase-targeted therapies work Cell Cycle 7 2008 1560 1563 (Pubitemid 351881321)
57. J.D. Dias, K. Guse, P. Nokisalmi, M. Eriksson, D.T. Chen, and I. Diaconu et al. Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures Eur J Cancer 46 2010 625 635
58. K. Lee, S.T. Yun, C.O. Yun, B.Y. Ahn, and E.C. Jo S100A2 promoter-driven conditionally replicative adenovirus targets non-small-cell lung carcinoma Gene Ther 19 2012 967 977
59. S. Libertini, I. Iacuzzo, G. Perruolo, S. Scala, C. Ierano, and R. Franco et al. Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947 Clin Cancer Res 14 2008 6505 6514
60. S. Libertini, A. Abagnale, C. Passaro, G. Botta, S. Barbato, and P. Chieffi et al. AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947 Endocr Relat Cancer 18 2011 129 141
61. N. Bagheri, M. Shiina, D.A. Lauffenburger, and W.M. Korn A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibition PLoS Comput Biol 7 2011 e1001085
62. P.A. Marks, and W.S. Xu Histone deacetylase inhibitors: potential in cancer therapy J Cell Biochem 107 2009 600 608
63. T. Watanabe, M. Hioki, T. Fujiwara, M. Nishizaki, S. Kagawa, and M. Taki et al. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells Exp Cell Res 312 2006 256 265 (Pubitemid 41814835)
64. Y. Watanabe, Y. Hashimoto, S. Kagawa, H. Kawamura, K. Nagai, and N. Tanaka et al. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells Cancer Gene Ther 19 2012 767 772
65. J. Ma, J. Zhao, J. Lu, Y. Jiang, H. Yang, and P. Li et al. Coxsackievirus and adenovirus receptor promotes antitumor activity of oncolytic adenovirus H101 in esophageal cancer Int J Mol Med 30 2012 1403 1409
66. N. Hoti, W. Chowdhury, J.T. Hsieh, M.D. Sachs, S.E. Lupold, and R. Rodriguez Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy Mol Ther 14 2006 768 778 (Pubitemid 44780612)
67. J. de Jonge, L.M. Berghauser Pont, S. Idema, J.J. Kloezeman, D. Noske, and C.M. Dirven et al. Therapeutic concentrations of anti-epileptic drugs do not inhibit the activity of the oncolytic adenovirus Delta24-RGD in malignant glioma J Gene Med 15 2013 134 141
68. A. Gros, C. Puig, S. Guedan, J.J. Rojas, R. Alemany, and M. Cascallo Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses Mol Ther 18 2010 903 911
69. A. Koski, M. Raki, P. Nokisalmi, I. Liikanen, L. Kangasniemi, and T. Joensuu et al. Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer Mol Ther 20 2012 221 229
70. S. Libertini, I. Iacuzzo, A. Ferraro, M. Vitale, M. Bifulco, and A. Fusco et al. Lovastatin enhances the replication of the oncolytic adenovirus dl1520 and its antineoplastic activity against anaplastic thyroid carcinoma cells Endocrinology 148 2007 5186 5194 (Pubitemid 350012617)
71. L. Xiao, X. Li, N. Niu, J. Qian, G. Xie, and Y. Wang Dichloroacetate (DCA) enhances tumor cell death in combination with oncolytic adenovirus armed with MDA-7/IL-24 Mol Cell Biochem 340 2010 31 40
72. M.A. Salako, H. Kulbe, C.K. Ingemarsdotter, K.J. Pirlo, S.L. Williams, and M. Lockley et al. Inhibition of the inflammatory cytokine TNF-alpha increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression Mol Ther 19 2011 490 499
73. N. Kondo, M. Tsukuda, M. Kimura, K. Fujita, A. Sakakibara, and H. Takahashi et al. Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma Oncol Rep 23 2010 355 363